Here, by demonstrating the synthetic lethal interaction between two ubiquitously expressed human paralogs VPS4A and VPS4B, we uncovered a novel therapeutic target to treat patients bearing VPS4B‐deficient cancers, for example, CRC used as a model in our study. This evidence concerns the gene VPS4B and colorectal carcinoma.